Nasus Pharma Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $44.2M
- Price
- $3.77
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.69%
- Volume
- 9.3K
About
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Quick stats
Shares outstanding11.7M
Computed float6.6M
Float / shares56.0%
Cash runway (months)8.5
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002029039
Websitehttps://www.nasuspharma.com
AI Summary
AI-generated1/23
minorbullishclinical trial
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma dosed the first patient in a Phase 1 pharmacokinetic trial of NS003, its intranasal powder formulation of ondansetron for CINV and PONV.
Pre-clinical data showed a PK profile comparable to IV ondansetron and a favorable safety profile at four times the test dose.
Topline PK data are expected before year-end, alongside a planned Q4 start of the pivotal NS002 intranasal epinephrine study for anaphylaxis.